Antinociceptive effect of botulinum toxin type A in rat model of Carrageenan and Capsaicin induced pain

Croatian Medical Journal

Volumn 46, Issue 2, 2005, Pages 201-208

  Bach Rojecky, Lidija ^b   Lacković, Zdravko ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; CARRAGEENAN;

ACETYLCHOLINE RELEASE; ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; INFLAMMATION; MALE; NONHUMAN; PAIN; PAW EDEMA; RAT;

ANIMALS; BOTULINUM TOXIN TYPE A; CAPSAICIN; CARRAGEENAN; HINDLIMB; HYPERALGESIA; MALE; MODELS, ANIMAL; NOCICEPTORS; PAIN; RATS; RATS, WISTAR;

EID: 13144276148     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27:552-8.
2. Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248 Suppl 1:3-10.
3. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43 Suppl 1:516-24.
4. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951-7.
5. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251 Suppl 1:11-7.
6. Relja M, Telarovic S. Botulinum toxin in tension-type headache. J Neurol. 2004;251 Suppl 1:112-4.
7. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109-15.
8. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56:1290-3.
9. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep. 2002;6:460-9.
10. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol. 2004;251 Suppl 1:18-11.
11. Smuts JA, Schuliz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache. 2004;44:801-5.
12. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg. 2004;30:452-5.
13. Jabbari B, Malier N, Difazio MP. Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 2003;4:206-10.
14. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871-5.
15. Bach-Rojecky L, Relja M, Lackovic Z. Botulinum toxin type A in pain management. In: Battistin L, editor. 7th Congress of the European Society for Clinical Neuropharmacology; Trieste 2004. MEDIMOND, Monduzzi Editore, International Proceedings, Bologna, pp. 185-190.
16. Silberstein S. Botulinum neurotoxins: origins and basic mechanisms of action. Pain Practice. 2004;4:S19-S26.
17. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-33.
18. Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol. 2004;172:1529-32.
19. Bach-Rojecky L, Relja M, Lackovic Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm. 2005;112:215-9.
20. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38:245-58.
21. Durham PL, Cady R, Cady R. Regulation of caldtonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35-42.
22. LaBuda CJ, Donahue R, Fuchs PN. Enhanced formalin nociceptive responses following LS nerve ligation in the rat reveals neuropathy-induced inflammatory hyperalgesia. Pain. 2001;94:59-63.
23. Radhakrishnan R, Moore SA, Sluka KA. Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain. 2003;104:567-77.
24. Honore P, Catheline G, LeGuen S, Besson JM. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats. Pain. 1997;71:99-108.
25. Tsuruoka M, Arai YC, Nomura H, Matsutani K, Willis WD. Unilateral hindpaw inflammation induces bilateral activation of the locus coeruleus and the nucleus subcoeruleus in the rat. Brain Res Bull. 2003;61:117-23.
26. Szolcsanyi J, Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides. 2004;38:377-84.
27. Gilchrist HD, Allard BL, Simone DA. Enhanced withdrawal responses to heat and mechanical stimuli following intraplantar injection of capsaicin in rats. Pain. 1996;67:179-88.
28. Kontinen VK, Aarnisalo AA, Idanpaan-Heikkila JJ, Panula P, Kalso E. Neuropeptide FF in the rat spinal cord during carrageenan inflammation. Peptides. 1997;18:287-92.
29. Winter CA, Risley EA, Muss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962;111:544-7.
30. Sun RQ, Lawand NB, Willis WD. The role of calcitonin gene-related peptide (CGRP) in the generation and maintenance of mechanical allodynia and hyperalgesia in rats after intradermal injection of capsaicin. Pain. 2003;104:201-8.
31. Menendez L, Lastra A, Hidalgo A, Baamonde A. Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice. J Neurosci Methods. 2002;113:91-7.
32. Randall LO, Salitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 1957;111:409-19.